Afamelanotide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This draft covers afamelanotide only for its approved EPP phototoxicity indication.

What the sources say

In two randomized placebo-controlled EPP trials, median pain-free direct-sunlight exposure was 6.0 versus 0.8 hours in the European study and 69.4 versus 40.8 hours in the U.S. study. These results concern adults with EPP, not general tanning or other conditions. (Human clinical trials; Langendonk et al., "Afamelanotide for Erythropoietic Protoporphyria," New England Journal of Medicine, 2015-07-02)
An observational study followed 115 patients with EPP over long-term use and reported sustained improvement in EPP-specific quality-of-life scores. Because the study was observational, it does not provide the same causal evidence as a randomized trial. (Small human studies; Biolcati et al., "Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria," British Journal of Dermatology, 2015-06-01)
SCENESSE is indicated for prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Its product information does not establish cosmetic tanning, general sun protection, or athletic benefits. (Manufacturer information; European Medicines Agency, SCENESSE: EPAR Product Information; updated 2026-10-07, 2026-10-07)
The product information reports no specific interaction studies and very limited pharmacokinetic data; it does not establish added benefit from combining afamelanotide with another drug, peptide, tanning agent, or supplement. (Manufacturer information; European Medicines Agency, SCENESSE: EPAR Product Information; updated 2026-10-07, 2026-10-07)
The product information lists hypersensitivity, severe hepatic disease, hepatic impairment, and renal impairment as contraindications. Hypersensitivity including anaphylaxis has been reported, and the implant may need removal if a serious reaction occurs. (Manufacturer information; European Medicines Agency, SCENESSE: EPAR Product Information; updated 2026-10-07, 2026-10-07)
Afamelanotide can darken existing pigmented lesions and increase generalized pigmentation; the product information recommends full-body skin examinations every 6 months. Nausea, headache, dizziness, fatigue, and implant-site reactions are among reported adverse effects. (Manufacturer information; European Medicines Agency, SCENESSE: EPAR Product Information; updated 2026-10-07, 2026-10-07)
The product information notes that interaction studies have not been performed and cautions that anticoagulants, aspirin, or NSAIDs may increase bruising or bleeding at the implant site. (Manufacturer information; European Medicines Agency, SCENESSE: EPAR Product Information; updated 2026-10-07, 2026-10-07)
The current October 2026 Poisons Standard lists afamelanotide in Schedule 4. This is Australian scheduling information and is distinct from the TGA product registration record. (Educator material (not peer reviewed); Federal Register of Legislation, Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, 2026-09-30)

Sources

Dosing, stacking and protocol details are not published here.